|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
1993-8-30
|
|
pubmed:abstractText |
Vaccination with native HBsAg results in both a humoral and a cellular immune response in humans. In individuals who responded to vaccination, the HBsAg (S region) specific response, as measured by cell proliferation, diminished significantly after 12 weeks, a time when the antibody response was still vigorous. Reduced and nonreduced HBsAg were equivalent in eliciting lymphocyte proliferation. Anti-MHC class II monoclonal antibodies were used in blocking studies to demonstrate that anti-HLA-DR but not anti-HLA-DQ or anti-HLA-DP inhibited specific lymphocyte proliferation to HBsAg. Both the monomer (reduced) and dimer (nonreduced) forms of an immunodominant midsequence HBsAg peptide (amino acid residues 139-146) produced lymphocyte proliferation roughly comparable to that induced by whole HBsAg in 6 of 7 responders immunized with whole HBsAg and the peptide-induced proliferation was blocked by anti-HLA-DR but not by anti-HLA-DP antibodies. These results suggest that HBsAg p 139-146 is a major immunodominant peptide of HBsAg and is restricted by HLA-DR.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0161-5890
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
941-8
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:8341285-Amino Acid Sequence,
pubmed-meshheading:8341285-Dose-Response Relationship, Immunologic,
pubmed-meshheading:8341285-HLA-DR Antigens,
pubmed-meshheading:8341285-Hepatitis B,
pubmed-meshheading:8341285-Hepatitis B Antibodies,
pubmed-meshheading:8341285-Hepatitis B Surface Antigens,
pubmed-meshheading:8341285-Hepatitis B Vaccines,
pubmed-meshheading:8341285-Humans,
pubmed-meshheading:8341285-Immunity, Cellular,
pubmed-meshheading:8341285-Immunization, Secondary,
pubmed-meshheading:8341285-Lymphocyte Activation,
pubmed-meshheading:8341285-Molecular Sequence Data,
pubmed-meshheading:8341285-Oxidation-Reduction,
pubmed-meshheading:8341285-Peptide Fragments,
pubmed-meshheading:8341285-T-Lymphocytes,
pubmed-meshheading:8341285-Time Factors,
pubmed-meshheading:8341285-Vaccination,
pubmed-meshheading:8341285-Vaccines, Synthetic
|
|
pubmed:year |
1993
|
|
pubmed:articleTitle |
Cellular recognition and HLA restriction of a midsequence HBsAg peptide in hepatitis B vaccinated individuals.
|
|
pubmed:affiliation |
Dana-Farber Cancer Institute, Boston, MA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
